Literature DB >> 21854404

Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus.

Chun Wang1, Lifang Lv, Yanzhi Yang, Dawei Chen, Guanjian Liu, Lihong Chen, Yuanxia Song, Liping He, Xiujun Li, Haoming Tian, Weiping Jia, Xingwu Ran.   

Abstract

OBJECTIVE: Glycemic variability is poorly studied in the nondiabetic individuals and newly diagnosed patients with type 2 diabetes. The aim of the study is to investigate the characteristics of glucose fluctuations in subjects with normal glucose tolerance (NGT), impaired glucose regulation (IGR) and newly diagnosed, drug-naïve type 2 diabetes mellitus (DM-2). DESIGN AND PATIENTS: This is a cross-sectional study of three groups including 53 subjects with IGR, 56 DM-2 patients and 53 NGT individuals. Monitoring by a continuous glucose monitoring system (CGMS(®) System Gold(™)) was performed for three consecutive days. MEASUREMENTS: Mean blood glucose (MBG), standard deviation of MBG (SDBG), largest amplitude of glycemic excursions (LAGE) and mean amplitude of glycemic excursions (MAGE) were calculated to estimate intraday blood glucose variability. Interday variability of glucose was evaluated by absolute means of daily differences (MODD). Postprandial glucose excursion (PPGE) was calculated to assess the influence of meals on glucose fluctuation.
RESULTS: Twenty-two percentage of NGT and 33.9% of IGR individuals experienced blood glucose ≥ 11.1 mmol/l; 49.1% of NGT, 50.9% of IGR and 30.8% of DM-2 participants had hypoglycemic episodes (CGM values <3.9 mmol/l). The IGR and DM-2 groups had greater SDBG (P = 0.010 and P < 0.001), LAGE (P = 0.014 and P < 0.001) and MAGE (P = 0.044 and P < 0.001) compared with the NGT group. Significantly greater MODD and PPGEs were found in the DM-2 groups than in the IGR and NGT groups (P < 0.001). The DM-2 patients had higher 72-MBG and glucose levels overnight than the NGT and IGR subjects (P < 0.001). In the patients with diabetes, MAGE was positively associated with MODD (r = 0.558, P < 0.001) and PPGEs (r = 0.738-0.843, P < 0.001).
CONCLUSIONS: Glucose variability is present to an increasing degree from NGT to IGR and IGR to DM-2. Compared with the NGT individuals, the IGR and DM-2 subjects show more predominant intraday glucose fluctuations. The DM-2 patients demonstrate increased PPGEs, higher glucose levels overnight and greater interday fluctuations.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21854404     DOI: 10.1111/j.1365-2265.2011.04205.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  30 in total

1.  Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels.

Authors:  Jian-Bin Su; Tong Chen; Feng Xu; Xue-Qin Wang; Jin-Feng Chen; Gang Wu; Yan Jin; Xiao-Hua Wang
Journal:  Endocrine       Date:  2013-09-13       Impact factor: 3.633

2.  Contributions of Basal Glucose and Postprandial Glucose Concentrations to Hemoglobin A1c in the Newly Diagnosed Patients with Type 2 Diabetes--the Preliminary Study.

Authors:  Xin Kang; Chun Wang; Dawei Chen; Lifang Lv; Guanjian Liu; Jie Xiao; Yanzhi Yang; Liping He; Lihong Chen; Xiujun Li; Haoming Tian; Weiping Jia; Xingwu Ran
Journal:  Diabetes Technol Ther       Date:  2015-03-31       Impact factor: 6.118

3.  Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3).

Authors:  Marie-Christine Vantyghem; Violeta Raverdy; Anne-Sophie Balavoine; Frédérique Defrance; Robert Caiazzo; Laurent Arnalsteen; Valéry Gmyr; Marc Hazzan; Christian Noël; Julie Kerr-Conte; Francois Pattou
Journal:  J Clin Endocrinol Metab       Date:  2012-09-20       Impact factor: 5.958

4.  Cross-Sectional and Individual Relationships between Physical Activity and Glycemic Variability.

Authors:  Joshua R Sparks; Mark A Sarzynski; J Mark Davis; Peter W Grandjean; Xuewen Wang
Journal:  Transl J Am Coll Sports Med       Date:  2022

5.  Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.

Authors:  Suk Chon; Yun Jung Lee; Gemma Fraterrigo; Paolo Pozzilli; Moon Chan Choi; Mi-Kwang Kwon; Sang Ouk Chin; Sang Youl Rhee; Seungjoon Oh; Young-Seol Kim; Jeong-Taek Woo
Journal:  Diabetes Technol Ther       Date:  2013-04-25       Impact factor: 6.118

6.  Effects of different proportion of carbohydrate in breakfast on postprandial glucose excursion in normal glucose tolerance and impaired glucose regulation subjects.

Authors:  Xin Kang; Chun Wang; Lv Lifang; Dawei Chen; Yanzhi Yang; Guanjian Liu; Hu Wen; Lihong Chen; Liping He; Xiujun Li; Haoming Tian; Weiping Jia; Xingwu Ran
Journal:  Diabetes Technol Ther       Date:  2013-04-17       Impact factor: 6.118

7.  Impact of incretin on early-phase insulin secretion and glucose excursion.

Authors:  Jie Shen; Zhi Chen; Chaofeng Chen; Xiao Zhu; Yajuan Han
Journal:  Endocrine       Date:  2013-01-03       Impact factor: 3.633

8.  Small changes in glucose variability induced by low and high glycemic index diets are not associated with changes in β-cell function in adults with pre-diabetes.

Authors:  Kristina M Utzschneider; Tonya N Johnson; Kara L Breymeyer; Lisa Bettcher; Daniel Raftery; Katherine M Newton; Marian L Neuhouser
Journal:  J Diabetes Complications       Date:  2020-04-18       Impact factor: 2.852

9.  Is type 2 diabetes really resolved after laparoscopic sleeve gastrectomy? Glucose variability studied by continuous glucose monitoring.

Authors:  D Capoccia; F Coccia; A Guida; M Rizzello; F De Angelis; G Silecchia; F Leonetti
Journal:  J Diabetes Res       Date:  2015-04-14       Impact factor: 4.011

Review 10.  Glycemic Variability: How Do We Measure It and Why Is It Important?

Authors:  Sunghwan Suh; Jae Hyeon Kim
Journal:  Diabetes Metab J       Date:  2015-08       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.